Schiff Nutrition and Aker BioMarine Sign Long-Term Krill Oil Supply Agreement
06 Julho 2011 - 8:00AM
Business Wire
Schiff Nutrition Group, Inc. a wholly owned subsidiary of Schiff
Nutrition International, Inc. (NYSE:WNI), and Aker BioMarine
(OSE:AKBM) expanded their supply agreement through at least June
2016 to provide Schiff high quality Aker BioMarine krill oil.
Further, Schiff is granted certain exclusive sales rights, and the
parties have agreed to collaborate on future innovations.
Schiff Nutrition is the maker of the world’s leading krill oil
brand, MegaRed®. Aker BioMarine, the supplier of Superba™ krill oil
and other krill based products, has undertaken to deliver up to 300
metric tons of krill oil per year.
“Determined to build world class operations and premium brands,
we strive to form long-term relationships with quality suppliers,”
said Tarang Amin, president and CEO of Schiff Nutrition
International. “Aker BioMarine delivers high quality Marine
Stewardship Council (MSC) certified krill oil. This agreement
secures a sustainable source capable of meeting our growth
aspirations. In addition, we have plans to leverage Aker
BioMarine’s expertise and collaborate on future krill products and
innovation."
“Schiff Nutrition, with its market leading MegaRed brand, offers
Aker BioMarine a long-term growth platform,” said Hallvard Muri,
CEO, Aker BioMarine. “We are pleased to partner with the company to
further develop the benefits of our phospholipid krill with no
fishy taste or smell. Schiff Nutrition has invested in growing this
category, and we look forward to working with the team on future
category-building initiatives.”
This information is subject of the disclosure requirements
pursuant to section 5-12 of the Norwegian Securities Trading
Act.
About Schiff Nutrition
Schiff Nutrition International, Inc. develops, manufactures,
markets and distributes branded and private label vitamins,
nutritional supplements and nutrition bars in the United States and
throughout the world. Schiff’s portfolio of well-known brands
includes Move Free®, Schiff® Vitamins, MegaRed®, Mega-D3™ and
Tiger's Milk®. To learn more about Schiff, please visit the web
site www.schiffnutrition.com.
About Aker BioMarine
Aker BioMarine is an integrated biotechnology company – uniquely
positioned to create high value krill derived biotech products. The
company is supplying biomarine ingredients through an optimized
value chain from raw materials to customer. Aker BioMarine utilizes
its unique krill harvesting to develop its own downstream
operations within the high value added nutraceutical and
aquaculture feed markets. Krill derived products, such as oil and
meal, have a high content of bioactive ingredients, e.g. Omega-3
bound phospholipids and astaxanthin, which have documented positive
effects on both humans and animals. Aker BioMarine has registered
Superba as the company`s brand name for nutraceutical and Qrill™ as
the company’s brand name for its krill meal and krill oil products
for aquaculture. Qrill™ has proven benefits to competing products
in the aquaculture market. To learn more about Aker BioMarine,
please visit the web site www.akerbiomarine.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that are based
on management’s beliefs and assumptions, current expectations,
estimates, and projections. These statements are subject to known
and unknown risks and uncertainties, certain of which are beyond
the company’s ability to control or predict, and therefore, actual
results may differ materially. Any forward-looking statements are
made pursuant to the Private Securities Litigation Reform Act of
1995 and, as such, speak only as of the date hereof. Schiff
Nutrition disclaims any obligation to update any forward-looking
statements whether as a result of new information, future events or
otherwise. You are cautioned not to place undue reliance on these
forward-looking statements.
Important factors that may cause actual results of Schiff
Nutrition to differ materially from those expressed or implied by
such forward-looking statements include, but are not limited to:
dependence on sales of our Move Free product and the joint care
category, dependence on sales of our MegaRed product, dependence on
individual customers, adverse publicity or consumer perception
regarding our nutritional supplements and/or their ingredients,
similar products distributed by other companies or the nutritional
supplement industry generally, the impact of competitive products
and pricing pressure (including expansion of private label
products), the inability to successfully bid on new and existing
private label business, the impact of raw material pricing,
availability and quality (particularly relating to joint care
products and ingredients from third-party suppliers outside the
United States, including China), claims that our products infringe
the intellectual property rights of others, the inability to
enforce or protect our intellectual property rights and proprietary
techniques against infringement, the inability to successfully
launch and maintain sales (especially in the joint care and omega-3
categories) outside of the United States while maintaining the
integrity of the products sold and complying with local
regulations, the inability to appropriately respond to changing
consumer preferences and demand for new products, the inability to
gain or maintain market distribution for new products or product
enhancements including products in the probiotic space, litigation
and government or administrative regulatory action in the United
States and internationally, including FDA enforcement and product
liability claims, the inability or increased cost to obtain
sufficient levels of product liability and general insurance, the
inability to comply with existing or new regulations, both in the
United States and abroad, and adverse actions regarding product
formulation, claims or advertising, product recalls or a
significant amount of product returns, dependence on a single
manufacturing facility and potential disruptions of our
manufacturing operations, the inability to find strategic
transaction opportunities or the inability to successfully
consummate or integrate a strategic transaction, the inability to
maintain or attract key personnel, interruptions to our information
technology systems, control by our principal stockholders, and
other factors indicated from time to time in the company’s SEC
reports, copies of which are available upon request from the
company’s investor relations department or may be obtained at the
SEC's web site (www.sec.gov). These
risks and uncertainties should be carefully considered before
making an investment decision with respect to shares of our common
stock.
Schiff Nutrit (NYSE:WNI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Schiff Nutrit (NYSE:WNI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024